SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

← catalyst calendar

NCT07187531 · readout ≤ 468 d

Sponsored by SAb Biotherapeutics, Inc. (industry) · SABS — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Other

Enrollment

159estimated

Sites

Countries

Australia, Austria, Belgium +12

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-11-25

actual

When the study began enrolling

Primary completion

Nov 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2028

estimated

The whole study's end, after follow-up

First posted

2025-09-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Type 1 Diabetes

Interventions

Drug: High Dose SAB-142
Drug: Low Dose SAB-142
Other: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs)

measured From dose administration through Week 4

Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT)

measured From dose administration up to Month 12

Permalink · SABS's whole pipeline · Catalyst calendar · Every registered study · What changed